51. 全身性強皮症 Scleroderma Clinical trials / Disease details


臨床試験数 : 523 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 113 - 標的パスウェイ数 : 214

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04789850
(ClinicalTrials.gov)
January 202210/2/2021Safety and Efficacy of Itacitinib in Adults With Systemic SclerosisSafety and Efficacy of Itacitinib in Adults With Systemic Sclerosis: a Phase II, Randomized, Controlled TrialSystemic SclerosisDrug: Itacitinib;Drug: PlaceboAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting18 YearsN/AAll74Phase 2France
2EUCTR2019-003430-16-FR
(EUCTR)
28/07/202002/06/2020Safety and efficacy of itacitinib in adults with systemic sclerosisSafety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial - SCLERITA - SCLERITA Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening
MedDRA version: 21.0;Level: LLT;Classification code 10012977;Term: Diffuse systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Itacitinib
Product Code: INCB039110
INN or Proposed INN: ITACITINIB
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
74Phase 2France